IP Library Granted Patent US 9,821,075
Granted Patent B2
US 9,821,075 · App. 15/132,130 · Granted Nov 21, 2017

Pharmaceutical compositions comprising meloxicam

Inventor: Herriot Tabuteau (New York, NY)
Assignee: AXSOME THERAPEUTICS, INC.
A61K47/48969A61K9/2009A61K31/4439A61K31/5415A61K45/06A61K47/02C08B37/0012C08B37/0015
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,821,075
App. No.
15/132,130
Filed
Apr 18, 2016
Granted
Nov 21, 2017
Kind
B2
Art Unit
1628
USPC
514/226.5
Abstract

Disclosed herein are compositions comprising an NSAID such as meloxicam in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of conditions such as pain.

Claims (19)

1. A dosage form comprising a complex of meloxicam and a sulfobutyl ether β-cyclodextrin (SBEβCD), and a bicarbonate, wherein the dosage form is an oral dosage form having a shorter T max of meloxicam than an otherwise identical reference dosage form that does not contain a SBEβCD or a bicarbonate, and wherein the complex is formed by mixing meloxicam and the cyclodextrin in a solution and drying the solution to form the complex.

2. The dosage form of claim 1 , wherein the SBEβCD has about 6 to about 7 sulfobutyl ether groups for each molecule of β-cyclodextrin.

3. The dosage form of claim 1 , wherein the bicarbonate comprises sodium bicarbonate.

4. The dosage form of claim 2 , wherein the meloxicam and the SBEβCD have a molar ratio of about 0.8 to about 1.2.

5. The dosage form of claim 1 , which is an oral dosage form.

6. The dosage form of claim 1 , wherein about 50 mg to about 200 mg of the SBEβCD is present in the dosage form.

7. The dosage form of claim 1 , wherein the bicarbonate is present in an amount of about 400 mg to about 600 mg.

8. The dosage form of claim 1 , further comprising an acid inhibitor.

9. The dosage form of claim 8 , wherein the acid inhibitor is a proton pump inhibitor.

10. The dosage form of claim 9 , wherein the proton pump inhibitor is esomeprazole.

11. The dosage form of claim 10 , wherein about 30 mg to about 50 mg of esomeprazole is present in the dosage form.

12. A method of administering meloxicam orally to a patient in need of treatment therewith, comprising orally administering the dosage form of claim 1 .

13. The method of claim 12 , wherein the bicarbonate is sodium bicarbonate.

14. The method of claim 13 , wherein the dosage form contains about 300 mg to about 600 mg of sodium bicarbonate.

15. The method of claim 12 , wherein the dosage form further comprises a proton pump inhibitor.

16. The method of claim 15 , wherein the proton pump inhibitor is esomeprazole, omeprazole, lansoprazole, pantoprazole, or rabeprazole.

17. The method of claim 12 , wherein the dosage form is administered to treat pain.

18. The method of claim 12 , wherein the dosage form is administered to treat inflammatory pain.

19. The method of claim 12 , wherein the dosage form is administered to treat osteoarthritis, rheumatoid arthritis, or juvenile rheumatoid arthritis.

Assignments (8)
RELEASE OF SECURITY INTEREST Recorded May 22, 2025
From: HERCULES CAPITAL, INC.
To: AXSOME THERAPEUTICS, INC.
Reel/Frame 071337/0004 →
SECURITY INTEREST Recorded May 9, 2025
From: AXSOME THERAPEUTICS, INC.; AXSOME MALTA LTD.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 071247/0836 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Sep 25, 2020
From: AXSOME THERAPEUTICS, INC.
To: HERCULES CAPITAL, INC., AS AGENT
Reel/Frame 053941/0491 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 8, 2017
From: TABUTEAU, HERRIOT
To: AXSOME THERAPEUTICS, INC.
Reel/Frame 044343/0453 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 21, 2017
From: ANTECIP BIOVENTURES II LLC
To: AXSOME THERAPEUTICS, INC.
Reel/Frame 043657/0690 →
CORRECTIVE ASSIGNMENT TO CORRECT THE SPELLING OF THE RECEIVING PARTY NAME PREVIOUSLY RECORDED ON REEL 039005 FRAME 0001. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jul 19, 2016
From: TABUTEAU, HERRIOT
To: ANTECIP BIOVENTURES II LLC
Reel/Frame 039391/0585 →
CORRECTIVE ASSIGNMENT TO CORRECT THE SPELLING OF THE ASSIGNEE'S NAME ON THE COVERSHEET PREVIOUSLY RECORDED AT REEL: 039005 FRAME: 0001. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jun 29, 2016
From: TABUTEAU, HERRIOT
To: ANTECIP BIOVENTURES II LLC
Reel/Frame 039206/0481 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 24, 2016
From: TABUTEAU, HERRIOT
To: ANTICEP BIOVENTURES II LLC
Reel/Frame 039005/0001 →
Continuity (4)
Continuation PCTUS2016026991 · Apr 11, 2016
Provisional Application 62114215 · Feb 10, 2015
Provisional Application 62259993 · Nov 25, 2015
Related Publication 20160228576A1 · Aug 11, 2016